Disclosed in the present application are: (i) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in therapy, (ii) a compound inhibiting the interaction between LSD1me2 and CHD1 for use in treating cancer, in particular prostate cancer, and (iii) a method of screening for such a compound.

Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

Flow apparatuses comprising a separation channel, a downstream flow separator, a detection zone, an observation zone, and a waste channel. The separation channel has first and second flows in contact and allows lateral movement of components between contacting first and second flows. The downstream flow separator is in communication with the separation channel and diverts a part of the first fluid flow, the second fluid flow, or both, from the separation channel. The detection zone comprises a detection channel downstream of and in communication with the flow separator and configured to receive a plurality of diverted flows from the flow separator and a label channel configured to label the diverted flows from the flow separator. The observation zone is configured to record an analytical signal indicative of the quantity and the electrical properties of the component. The waste channel is at the downstream end of the observation zone.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Monoclonal antibodies against bacterial proteins that confer resistance to the antibiotic colistin and hybridomas that produce such monoclonal antibodies are described. The monoclonal antibodies have a strong affinity for MCR proteins and may be used in detection methods and kits to detect the presence of MCR proteins including variants thereof in a sample.

Methods, devices, and systems are disclosed for performing high throughput analysis of conformational change in biological molecules or other biological entities using surface-selective nonlinear optical detection techniques.

The present invention provides a method of stratifying a patient suffering from CKD into one of stages 1-3 of CKD, comprising determining the level of the biomarkers FABP1, -GT, AST, creatinine and cystatin C in a sample obtained from the patient and comparing the level of FABP1 in the sample to a control value and the levels of -GT, AST, creatinine and cystatin C in the sample to a range of control values for each biomarker, wherein an increased level of FABP1 compared to the control value and levels of -GT, AST, creatinine and cystatin C within the range of control values for each biomarker indicate that the patient suffers from stage 1 CKD or wherein an increased level of FABP1 compared to the control value, levels of -GT and AST within the range of control values for each biomarker, and increased levels of creatinine and cystatin C compared to an upper threshold of the control range for these biomarkers indicate that the patient suffers from stage 2 or stage 3 CKD.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.